Zobrazeno 1 - 10
of 45
pro vyhledávání: '"JASON L. GAGLIA"'
Autor:
Piotr Witkowski, Louis H. Philipson, John B. Buse, R. Paul Robertson, Rodolfo Alejandro, Melena D. Bellin, Fouad Kandeel, David Baidal, Jason L. Gaglia, Andrew M. Posselt, Roi Anteby, Piotr J. Bachul, Yaser Al-Salmay, Kumar Jayant, Angelica Perez-Gutierrez, Rolf N. Barth, John J. Fung, Camillo Ricordi
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2022)
Clinical islet allotransplantation has been successfully regulated as tissue/organ for transplantation in number of countries and is recognized as a safe and efficacious therapy for selected patients with type 1 diabetes mellitus. However, in the Uni
Externí odkaz:
https://doaj.org/article/8ce3c7aabdf24c8ebc54e4691f1ff99f
Autor:
Carla J. Greenbaum, Elisavet Serti, Katharina Lambert, Lia J. Weiner, Sai Kanaparthi, Sandra Lord, Stephen E. Gitelman, Darrell M. Wilson, Jason L. Gaglia, Kurt J. Griffin, William E. Russell, Philip Raskin, Antoinette Moran, Steven M. Willi, Eva Tsalikian, Linda A. DiMeglio, Kevan C. Herold, Wayne V. Moore, Robin Goland, Mark Harris, Maria E. Craig, Desmond A. Schatz, David A. Baidal, Henry Rodriguez, Kristina M. Utzschneider, Hendrik J. Nel, Carol L. Soppe, Karen D. Boyle, Karen Cerosaletti, Lynette Keyes-Elstein, S. Alice Long, Ranjeny Thomas, James G. McNamara, Jane H. Buckner, Srinath Sanda, for the ITN058AI EXTEND Study Team
Publikováno v:
JCI Insight, Vol 6, Iss 21 (2021)
Background IL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in
Externí odkaz:
https://doaj.org/article/083a57294536479793c92cf07ad43e13
The demise of islet allotransplantation in the United States: A call for an urgent regulatory update
Autor:
Rolf N. Barth, Mark A. Hardy, Dixon B. Kaufman, Raghavendra G. Mirmira, Piotr Witkowski, David A. Baidal, Raja Kandaswamy, Louis H. Philipson, Chirag S. Desai, Melena D. Bellin, Piotr J. Bachul, Jason L. Gaglia, John J. Fung, Michelle A. Josephson, Oyedolamu K. Olaitan, Jonathan A. Fridell, John B. Buse, Peter G. Stock, Jason R. Wellen, Peter L. Abrams, Robert C. Harland, Bashoo Naziruddin, Jordan Pyda, Amittha Wickrema, Camillo Ricordi, Marwan S Abouljoud, Lloyd E. Ratner, Silke V. Niederhaus, Tomasz Kozlowski, Michael Charlton, Kumar Jayant, David C. Mulligan, R. Paul Robertson, James F. Markmann, Rachael C. Forbes, Robert J. Stratta, J. Michael Millis, Anthony J. Japour, Jon S. Odorico, Marlon F. Levy, Rodolfo Alejandro, Fouad Kandeel, Appakalai N. Balamurugan, Kenneth A. Andreoni, Yolanda T. Becker
Publikováno v:
Am J Transplant
Islet allotransplantation in the United States (US) is facing an imminent demise. Despite nearly three decades of progress in the field, an archaic regulatory framework has stymied US clinical practice. Current regulations do not reflect the state-of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91b5a670acb860ed30eb832257b474fa
https://doi.org/10.1111/ajt.16397
https://doi.org/10.1111/ajt.16397
Publikováno v:
Diabetes. 71
Type 1 Diabetes (T1D) is an autoimmune disease characterized by selective loss of pancreatic β-cells. Aberrant reactivity to insulin and insulin precursor peptides has long been considered important in the pathogenesis of T1D. Recently, T cells reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a8d23619e46d8f71728c3655c33eb5f
https://doi.org/10.2337/db22-184-or
https://doi.org/10.2337/db22-184-or
Autor:
LORI M. LAFFEL, JINGWEN LIU, LINA TITIEVSKY, KAITLIN HAGAN, TINA LIU, KEVAL CHANDARANA, JASON L. GAGLIA, WENDY WOLF, JEOFFREY BISPHAM, KATHERINE S.M. CHAPMAN, DANIEL FINAN, RICHARD M. BERGENSTAL
Publikováno v:
Diabetes. 71
Continuous glucose monitoring (CGM) metrics and self-reported disease characteristics (severe hypoglycemic events [SHEs], HbA1c) warrant further description in people with T1D using CGM and pumps, including hybrid closed-loop systems (HCLS) . We cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c90e51939d0398b6a3bdf4033b879c21
https://doi.org/10.2337/db22-652-p
https://doi.org/10.2337/db22-652-p
Autor:
JEREMY PETTUS, JINGWEN LIU, LINA TITIEVSKY, KAITLIN HAGAN, TINA LIU, KEVAL CHANDARANA, JASON L. GAGLIA, WENDY WOLF, JEOFFREY BISPHAM, KATHERINE S.M. CHAPMAN, DANIEL FINAN, JENNIFER SHERR
Publikováno v:
Diabetes. 71
Trials of continuous glucose monitors (CGMs) and hybrid closed-loop systems (HCLS) demonstrate improvements in glycemia with reductions in hypoglycemia in T1D, but there is limited real-world data on how these technologies impact the prevalence of im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d493d8c34000ae8616fe3da3c1be0419
https://doi.org/10.2337/db22-92-or
https://doi.org/10.2337/db22-92-or
Autor:
Kevan C. Herold, Peter A. Gottlieb, Louis H. Philipson, James Dziura, David A. Baidal, Ruth S. Weinstock, Jason L. Gaglia, Rodica Pop-Busui, Jennifer B. Marks, Stephen E. Gitelman, Jesse Reynolds
Publikováno v:
Diabetes, obesity & metabolism, vol 22, iss 11
Diabetes Obes Metab
Diabetes Obes Metab
AIMS: To test whether a long-acting GLP-1 receptor agonist would improve glucose control in patients with type 1 diabetes (T1D) and to determine whether the presence of residual beta cell function would affect the response. In addition, we sought to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1c923f3404bac8533ff93ea3c5316af
https://doi.org/10.1111/dom.14121
https://doi.org/10.1111/dom.14121
Autor:
Antoinette Moran, S. Alice Long, Philip Raskin, James McNamara, William E. Russell, Carol L. Soppe, Sai Kanaparthi, Elisavet Serti, Hendrik J. Nel, Kevan C. Herold, Sandra Lord, Lia J Weiner, Steven M. Willi, Lynette Keyes-Elstein, Kurt J Griffin, Robin Goland, Ranjeny Thomas, Stephen E. Gitelman, Mark Harris, Henry Rodriguez, Karen Cerosaletti, Linda A. DiMeglio, Darrell M. Wilson, Itn Ai Extend Study Team, Wayne V. Moore, Srinath Sanda, Carla J. Greenbaum, Maria E. Craig, David A. Baidal, Kristina M. Utzschneider, Jason L. Gaglia, Katharina Lambert, Eva Tsalikian, Karen D. Boyle, Desmond A. Schatz, Jane H. Buckner
Publikováno v:
JCI Insight
JCI insight, vol 6, iss 21
JCI insight, vol 6, iss 21
Background IL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be015273c4208eb40c963e69de86cd2c
http://europepmc.org/articles/PMC8663550
http://europepmc.org/articles/PMC8663550
Autor:
Stephan Kissler, Jason L. Gaglia
Publikováno v:
Biochemistry. 58:4107-4111
Type 1 diabetes (T1D) is an autoimmune disease characterized by an insulin deficiency. Ever since the discovery of insulin almost 100 years ago, patients with T1D have relied on multiple daily insulin injections to survive an otherwise deadly disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a798143e269f9306d18b304c6bb3de
https://doi.org/10.1021/acs.biochem.9b00707
https://doi.org/10.1021/acs.biochem.9b00707
Autor:
Kenneth A. Andreoni, Beth Schrope, Robert C. Harland, R. Paul Robertson, John B. Buse, Ling-Jia Wang, Jordan Pyda, Oyedolamu K. Olaitan, Yolanda T. Becker, Mark A. Hardy, Roi Anteby, Gregory L. Szot, Piotr Witkowski, Piotr J. Bachul, Chirag S. Desai, Jon S. Odorico, Silke V. Niederhaus, Martin Wijkstrom, Fouad Kandeel, Raja Kandaswamy, Michelle A. Josephson, Tomasz Kozlowski, Peter L. Abrams, Jason L. Gaglia, Joseph R. Leventhal, Wanxing Cui, Shakir Hussein, Camillo Ricordi, Andrew M. Posselt, Robert J. Stratta
Publikováno v:
Journal of clinical medicine, vol 10, iss 13
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 2878, p 2878 (2021)
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 2878, p 2878 (2021)
The Food and Drug Administration (FDA) has been regulating human islets for allotransplantation as a biologic drug in the US. Consequently, the requirement of a biological license application (BLA) approval before clinical use of islet transplantatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649fe399a90d397c08b684c080c26a6a
https://escholarship.org/uc/item/1236c9p6
https://escholarship.org/uc/item/1236c9p6
